{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"dataset_type":["N/A"],"full_dataset_link":["https://ega-archive.org/datasets/EGAD00001006439"],"sample_count":["0"],"description":["EGA dataset EGAD00001006439"],"repository":["EGA"],"title":["20201006_EGA_MELA_CRKL_RNA"],"pubmed_abstract":["Melanoma of the skin is a common cancer only in Europeans, whereas it arises in internal body surfaces (mucosal sites) and on the hands and feet (acral sites) in people throughout the world. Here we report analysis of whole-genome sequences from cutaneous, acral and mucosal subtypes of melanoma. The heavily mutated landscape of coding and non-coding mutations in cutaneous melanoma resolved novel signatures of mutagenesis attributable to ultraviolet radiation. However, acral and mucosal melanomas were dominated by structural changes and mutation signatures of unknown aetiology, not previously identified in melanoma. The number of genes affected by recurrent mutations disrupting non-coding sequences was similar to that affected by recurrent mutations to coding sequences. Significantly mutated genes included BRAF, CDKN2A, NRAS and TP53 in cutaneous melanoma, BRAF, NRAS and NF1 in acral melanoma and SF3B1 in mucosal melanoma. Mutations affecting the TERT promoter were the most frequent of all; however, neither they nor ATRX mutations, which correlate with alternative telomere lengthening, were associated with greater telomere length. Most melanomas had potentially actionable mutations, most in components of the mitogen-activated protein kinase and phosphoinositol kinase pathways. The whole-genome mutation landscape of melanoma reveals diverse carcinogenic processes across its subtypes, some unrelated to sun exposure, and extends potential involvement of the non-coding genome in its pathogenesis."],"pubmed_title":["Whole-genome landscapes of major melanoma subtypes."],"pubmed_authors":["Hayward Nicholas K NK, Wilmott James S JS, Waddell Nicola N, Johansson Peter A PA, Field Matthew A MA, Nones Katia K, Patch Ann-Marie AM, Kakavand Hojabr H, Alexandrov Ludmil B LB, Burke Hazel H, Jakrot Valerie V, Kazakoff Stephen S, Holmes Oliver O, Leonard Conrad C, Sabarinathan Radhakrishnan R, Mularoni Loris L, Wood Scott S, Xu Qinying Q, Waddell Nick N, Tembe Varsha V, Pupo Gulietta M GM, De Paoli-Iseppi Ricardo R, Vilain Ricardo E RE, Shang Ping P, Lau Loretta M S LMS, Dagg Rebecca A RA, Schramm Sarah-Jane SJ, Pritchard Antonia A, Dutton-Regester Ken K, Newell Felicity F, Fitzgerald Anna A, Shang Catherine A CA, Grimmond Sean M SM, Pickett Hilda A HA, Yang Jean Y JY, Stretch Jonathan R JR, Behren Andreas A, Kefford Richard F RF, Hersey Peter P, Long Georgina V GV, Cebon Jonathan J, Shackleton Mark M, Spillane Andrew J AJ, Saw Robyn P M RPM, López-Bigas Núria N, Pearson John V JV, Thompson John F JF, Scolyer Richard A RA, Mann Graham J GJ"],"name_synonyms":["Grb-2, AA589403, Grb2/drk, CG6033, Drk/Grb2, l(2)10626, l(2)k13809, P1112, AI325100, 24/1, E(sev)2B, 1110025F07Rik, Grb2, GRB2, Su(sev)R1., Grb/drk, Crkol, Drk, DRK, DmelCG6033, crkl"],"description_synonyms":["cutaneous melanoma, Melanoma of the Skin, ALM, Molecular Biology, Malignant Melanoma of Skin, sequencing_assay, melanoma of the skin, Malignant melanoma of skin (disorder), RNA-seq  (transcriptome sequencing), Melanoma of skin, malignant scalp melanoma, malignant melanoma of skin stage unspecified, MM - Malignant melanoma of skin, Malignant melanoma of other specified skin site, Illumina, zone of skin melanoma (disease), unspecified (disorder), malignant lower limb melanoma, cancer of skin, Melanoma of Skin, palmar/plantar melanoma, site unspecified, SEQUENCING, unspecified, Biopolymer Sequencing, Melanoma, sequencing assay, malignant melanoma of skin, melanoma, stage unspecified, malignant neck melanoma, Whole Transcriptome Shotgun Sequencing, NOS, malignant melanoma of skin of trunk except scrotum, Transcriptome Sequencing, Illumina Sequencing Technology, Malignant melanoma of skin NOS (disorder), subungual melanoma., Stage Unspecified, Skin, malignant melanoma (of skin), Malignant Melanoma (of Skin), melanoma of skin, Malignant melanoma of skin, Total RNA Sequencing, Malignant melanoma of skin of other and unspecified parts of face, malignant lip melanoma, acral lentiginous malignant melanoma of skin, malignant ear melanoma, Malignant Cutaneous Melanoma, skin, Nucleic Acid Sequencing, Illumina Sequencing, malignant trunk melanoma, malignant melanoma of ear and/or external auricular canal, Whole Transcriptome Sequencing, WTSS, Malignant melanoma of other specified skin site (disorder), zone of skin melanoma, MALIG MELANOMA SKIN NEC, Sequencing, cutaneous melanoma (disease), NUCLEIC ACID SEQUENCING, malignant melanoma of skin of lower limb, melanoma (disease) of zone of skin, [X]Malignant melanoma of skin, Malignant melanoma of other specified sites of skin, MALIG MELANOMA SKIN NOS, cutaneous (skin) melanoma, acral melanoma, malignant cutaneous melanoma, malignant melanoma of skin of upper limb, RNAseq, malignant upper limb melanoma, Whole-Transcriptome Sequencing, WHOLE TRANSCRIPTOME SEQUENCING, RNA Sequencing, skin melanoma, RNA-Seq, Total RNA-Seq, Sequence Analysis, MAL MELANOM FACE NEC/NOS"],"pubmed_title_synonyms":["melanoma (disease), malignant melanoma, Melanomas, whole genome, Melanoma, Malignant Melanomas, melanoma, Naevocarcinoma., Genomes, Malignant, malignant, Malignant Melanoma"],"pubmed_abstract_synonyms":["Unknown/Not Stated, 145kDa, DmErk, pp44mapk, Materials, telomere, p19<ARF>, Ray, Unknown if Chief Complaint Caused by Trauma, A1, Not Known if MET Mutation Analysis Was Performed, raf, Biochemical Pathway, Unknown Tamoxifen Use, Tumor, Xnp, Alternative, subungual melanoma, ATP-protein transphosphorylase activity, Summary Report, type I, nuclear chromosome, AA120551, Protein Kinases, Kinase, Not Known if ROS1 Rearrangement Analysis Was Performed, SEM, Documentation Unknown, Unrelated to Intervention, E030030H24Rik, Gene Variation, Involvement, stimulation by symbiont of host programmed cell death, Unknown Clark Level, Dsor2, U, MALIG MELANOMA SKIN NEC, Not Known if NF1 Mutation Analysis Was Performed, D-raf1, Not Known if KRAS Mutation Analysis Was Performed, INSDC_feature:telomere, Tumors, ERK-A, Unknown Procedure Type for New Tumor Event, Unknown Age When Started using Smokeless Tobacco after Regular Use, dpERK, anatomical protrusion, Unknown History of Gestational Complication, mutagenesis, betaIIPKC, DmMAPK, Light, Malignant Melanomas, Alpha thalassemia intellectual disability syndrome, dp-ERK, cRaf, SHS, UV Light, Adjuvant Post-operative Chemotherapy Administration Unknown, Wee-kinase activity, New Tumor Event After Initial Treatment Unknown, Sap155, attributable, Benign, malignant melanoma of skin, stage unspecified, Recklinghausen's disease, Attribution, Gene Variation Negative, Genetic Alteration, MRXS3, pMAPK, Diverse, Unknown History of Other Muscular Dystrophy or Glycogen Storage Disorder, 155kDa, Unknown if Routine Cytogenetics were Completed, Malignant melanoma of skin of other and unspecified parts of face, l(1)pole hole, CRAF, NRAS, UNK, Benign Neoplasms, ZNF-HX, l(2)41Ac, whole genome, D-raf, First Course Treatment Completion Measure of Success of Outcome Unknown, Malignant Neoplasms, Cutaneous Route of Administration, Not Known if Additional Molecular Studies Were Performed, Report, CT34260, CMD1NN, dpERk, People, MITOGEN-ACTIVATED PROTEIN KINASE, Koerper, SAPK, WSS, Previous, mitogen-activated protein kinase 1, Wee 1-like kinase activity, AA473386, SF3b1, CDKN2, MAL MELANOM FACE NEC/NOS, TA-8, telomeric region, Chemical/Occupational Exposure History Unknown, Malignant melanoma of skin (disorder), Neoplasms, regulation by symbiont of host system process, glycogen synthase kinase 3 activity, Traverse, Evidence of Disease Unknown after Completion of Therapy, number, F14N23.9, DRaf, Affected, palmar/plantar melanoma, Not Known if IDH Family Mutation Analysis Was Performed, Unrelated, mutation, ALPS4, Adjuvant Post-operative Immunological Therapy Administration Unknown, ribosomal protein S6 kinase II activity, Medical, D-Raf, Erk, Additional Surgery for New Tumor Event Unknown, protein-serine kinase activity, UV Radiation, Unknown Use of Menopausal Hormone Therapy, Clinical, Pathologic Process Resolution, malignant trunk melanoma, Naevocarcinoma, STK32, PCBC, Unknown if Targeted Molecular Therapy Was Administered as an Additional Treatment for a New Tumor Event, C87398, Not Known if 10q23/PTEN Locus Deletion Analysis Was Performed, Former, Phl, Nf-1, erk, melanoma (disease) of zone of skin, Neoplasias, Malignant melanoma of other specified sites of skin, Unknown Oral Contraceptive Use, Draf, rll, skin melanoma, Not Mutated, STK26, Investigative Reports, NF-1, nf1, p38-2, von Reklinghausen disease, Unknown History of Myopathy, myelin basic protein kinase activity, Follow-Up Form Completion Outcome Measure of Success Unknown, Adjuvant Post-operative Targeted Molecular Therapy Administration Unknown, New, Malignant Melanoma of Skin, Ultra-Violet Rays, Unknown History of Kawasaki Disease, TP16, DRT, Malignant Neoplasm, Actinic, NRAS1, hemolysin activity, body, ATR2, Melanoma of skin, stress-activated kinase activity, MAP-2 kinase activity, BRAF1, whole body, Not Known if ATRX Mutation Analysis Was Performed, p16INK4a, MDS, protein phosphokinase activity, Genetic Change, MT, ATRX, P14ARF, affected, stress-activated protein kinase activity, Research Reports, chemical analysis, Prp10, Hsh155, Performance Status Scale Timing Unknown, Unknown if Hormone Therapy Was Administered as an Additional Treatment for a New Tumor Event, Intercurrent Illness is Unknown at Onset of Chief Complaint, Skin, Mutation, protein kinase p58 activity, Ultra-Violet, Hypertension Unknown, P16INK4A, serine/threonine protein kinase activity, Unknown Dosage Form Category, Nondeletion type, CG12559, Ultraviolet, dpERK1, Von Recklinghausen disease, Negated, dsk1, malignant tumor, Not Known if Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Performed, atypical PKC activity, Hands, INK4a-ARF, No, l(1)polehole/draf, DXHXS6677E, Hp1bp2, Rad54, Braf2, Feet, Multiple Known Primary Tumors Unknown at Initial Melanoma Diagnosis, Gene Mutation, UNKNOWN, protein serine-threonine kinase activity, Neoplasia, SAP kinase activity, mucosa, Unknown History of Non-Cardiac Surgery, glycogen synthase kinase activity, Melanoma of the Skin, SF3b145, protein kinase A activity, Mpk2, Cus1, p42mapk, Actinic Rays, Tp53, SR2-1, Mitogen Activated Protein Kinase, XLMR hypotonic face syndrome, melanoma, Mitogen-Activated Protein, 2610311M13Rik, DKCB4, kinase-related transforming protein, pathogenesis, malignant melanoma of skin of trunk except scrotum, Arf, Unknown Daily Fluid Intake, SF3b155, SF3b150, Unknown Site of New Tumor Event, NCMS, Targ4, N-ras, Gene Mutation Negative, Identification, Not Known if EGFR Mutation Analysis Was Performed, DKCA2, Not Known if PDGFRA Mutation Analysis Was Performed, DERK-A, MTS-1, type 1 neurofibromatosis, Craf1, E(sina)7, Rl, Raf kinase activity, Novel, serine kinase activity, MP kinase activity, atypical protein kinase C activity, Great, mitogen-activated S6 kinase activity, P14, protein-aspartyl kinase activity, P16, dERK, D6Ertd631e, P19, P16-INK4A, Ultraviolet Ray, TR, Gene Mutant, Mitogen-Activated, Cancer History Unknown, Mapk, Not Known if Immunohistochemistry Was Performed, MLM, Ultraviolet Radiations, ERK1, p16, ERK2, mapk1a, malignant lower limb melanoma, UV, M phase-specific cdc2 kinase activity, Not Known if ALK Rearrangement Analysis Was Performed, Melanoma, Neither Case or Control Status, Involved, mapk1b, MapK, Non, Not, Unknown if Chemotherapy Was Administered as an Additional Treatment for a New Tumor Event, dNF1, erk2, l(1)G0475, 1p/19q Codeletion Status Unknown, phosphorylase B kinase kinase activity, ERKa, Not Known if Peripheral Blood Immunophenotyping and Cytochemistry Were Performed, BcDNA:RE08694, l(2R)EMS45-39, Draf1, raf1, CAPB, Attributable, AA387315, DmelCG12559, p38, Gene Mutant Negative, DpErk, ERKA, hydroxyalkyl-protein kinase activity, Unknown if Chief Complaint was Witnessed, WEE1Hu, P53, telomeric DNA, p44, C110, Gene Variant, molecular pathway, AV095280, rafl, Resolved License, Non-, calcium/phospholipid-dependent protein kinase activity, Unknown Route of Administration, p53, Malignant, 4833408C14Rik, Hek5, Investigative, nondeletion type, HP1-BP38, Adjuvant Post-operative Radiation Therapy Administration Unknown, Gene Variant Negative, Unknown if Subsequent Known Primary Melanoma(s) Found During the Follow-Up, SFM1, Malignant melanoma of skin NOS (disorder), mucosal melanoma, Malignant melanoma of skin, T-antigen kinase activity, Site, cutaneous, galactosyltransferase-associated kinase activity, XH2, Mitogen-Activated Protein Kinase, Diversity, DmelCG2845, Ultra-Violet Ray, zone of skin melanoma, Transphosphorylase, mucous membrane, CG18732, protein kinase (phosphorylating) activity, AI447451, l(1)raf, Physiologic Resolution, Gene Mutation Not Detected, TRP53, casein kinase (phosphorylating) activity, Unknown History of Illicit Drug Use, GENETIC_SEQ, ert1, activation by organism of non-apoptotic programmed cell death in other organism, P16INK4, malignant, Immunotherapy Status Unknown, Xp53, Alpha-thalassemia/intellectual disability syndrome, neurofibromatosis type 1 microdeletion syndrome, 2.7.11.1, Actinic Ray, AP50 kinase activity, MBP kinase I activity, Not Known if Additional Immunohistochemistry Was Performed, malignant melanoma (of skin), Ultra Violet Rays, Resolution, Xp42, Chemical/Occupational Exposure Type Unknown, Cross, Kinases, mitogen activated kinase activity, malignant melanoma of ear and/or external auricular canal, Su(Raf)2B, CDK4I, Not Known if Additional Testing Was Performed, cutaneous melanoma (disease), malignant melanoma of skin of lower limb, Alternate, D-ERK, alternative, D830050J10Rik, Braf-2, PFBMFT1, Alpha-thalassemia X-linked intellectual disability syndrome, P19ARF, Cutaneous use, RAF, Not Known if EGFR Amplification Analysis Was Performed, Summary, Field Report, A-kinase activity, MAP kinase 1 activity, Unknown if Another form of Birth Control was Used, Similarity, extracellular signal-regulated kinase activity, Ultraviolet Black Lights, Tyro5, Across, Progress Reports, ALPHA-thalassemia/mental retardation syndrome, XNP, hTRT, Prp4 protein kinase activity, Mutations, DmelCG8318, unspecified, LeMPK3, p44mpk, bbl, ATP:protein phosphotransferase (non-specific) activity, Dp38, ARF-INK4a, SAPK2, Not Known if Fluorescence In Situ Hybridization Was Performed, p16(INK4a), Sem, peripheral type, Gene Variation Not Detected, Not Known if PTEN Mutation Analysis Was Performed, Tumor Progression Unknown After Initial Treatment, MAP-k, Progress Report, Genomes, BCC7, Draf-1, pp42, EK5, Pathways, 932, Not Known if BRAF Rearrangement Analysis Was Performed, sem, Mutation Abnormality, high frequency, Field Reports, ATP Phosphotransferases, Adverse Event Unrelated to Intervention, Hp1bp38, Unknown Molecular Analysis, p82 kinase activity, Pathway, Radiation, dpErk, Not Known if 1p/19q Deletion Analysis Was Performed, l(1)phl, Gene Mutation Detected, Alpha thalassemia mental retardation syndrome, Resolution of Pathologic Process, PMK-2, PMK-1, Unknown if Interferon Gamma Treatment was Administered Prior to Specimen Resection, telomeric sequence, PMK-3, pMapK, bfy, v-Raf, DNA Sequence, Not Known if Mutation Analysis Was Performed, Regular Smokeless Tobacco Use for Six Weeks or More Unknown, DmERKA, whole organism, rl/MAPK, TCS1, Unknown History of Congenital Heart Disease, Field, non-specific serine/threonine protein kinase activity, l(1)polehole, ALPHA-thalassemia/intellectual disability syndrome, cutaneous (skin) melanoma, Material, Neither Case nor Control, serine-specific protein kinase activity, activation by symbiont of host programmed cell death, HIPK2, Ultraviolet Light, cytidine 3', bhy, EG:BACH48C10.3, BB129353, INK4A, Pathology Resolution, Nucleotide Sequence, Cutaneous, Molecular Abnormalities Unknown, Unknown Number of Full Term Pregnancies, X-linked, glycogen synthase A kinase activity, Potential, INK4, 12559, Not Known if BRAF Mutation Analysis Was Performed, LFS1, draf, phosphorylase b kinase kinase activity, unspecified (disorder), Not Known if ERBB2 Mutation Analysis Was Performed, EK2-1, site unspecified, melanoma (disease), Structural, induction by organism of non-apoptotic programmed cell death in other organism during symbiotic interaction, Sites, causality., TP2, Malignant Melanoma (of Skin), D-RAF, Gene Variant Positive, ERK, Negation, skin, MUCOSA, Not Known if Lymph Node Dissection Was Performed, NFNS, Mitogen Activated Protein Kinases, Structure, VRNF, Solution, Unknown Daily Salt Intake, Unknown if Immunotherapy Was Administered as an Additional Treatment for a New Tumor Event, {Unknown}, protein-cysteine kinase activity, Gene Variation Detected, Resolve, Hpr kinase activity, p19ARF, NF1, Cancer, Not Known if NRAS Mutation Analysis Was Performed, ALM, Use of Smokeless Tobacco at Time of Diagnosis Unknown, raf-1, TRT, CUTANEOUS, protein serine kinase activity, p19-lt-ARF-gt-, PRP10, Melanoma of Skin, Sequences, Mucosal, PKA, PKC, Malignant Melanoma, mapk2, mapk1, Neoplasm, Mutageneses, AA990557, INSDC_feature:regulatory, AA409119, Paraneoplastic Syndrome Status is Unknown, primary cancer, Unknown if Patient Has Genetic Syndrome Associated with Congenital Heart Defect, Malignant Cutaneous Melanoma, Not Known, Unknown Data Entry Method, Similar, Cancers, 5'-cyclic monophosphate-responsive protein kinase activity, Tumor Laterality Unknown, Not Known if SDH Complex Mutation Analysis Was Performed, Reports, dpMAPK, malignant cutaneous melanoma, RAD54, ph, MTS1, c-Raf, Previously, Dermal, determination, malignant scalp melanoma, positive regulation by symbiont of host non-apoptotic programmed cell death, Unknown, Pctr1, CUTAN, cancer of skin, SAP145, hEST2, mitogen-activated protein kinase activity, ARF, SF3B145, Alpha-thalassemia-X-linked intellectual disability syndrome, animal, mpk1, Summary Reports, Chemotherapy Status Unknown, acral lentiginous malignant melanoma of skin, Erk/Map kinase, Malignant melanoma of other specified skin site (disorder), Black Light, 9930012E13Rik, Unknown if Medication Taken, Progress, [X]Malignant melanoma of skin, Unknown: Could not be determined or unsure, DERK, C230098H17, malignant neoplasm, malignant melanoma of skin of upper limb, MBP kinase II activity, Malignancies, ATP, ATR, cutaneous melanoma, 6430402F14Rik, B-RAF1, MAP kinase 2 activity, melanoma of the skin, Unknown Daily Caloric Intake, CG8318, Erk1, Metabolic Network, MM - Malignant melanoma of skin, Malignant melanoma of other specified skin site, Ultraviolet Radiation, Tumor Location Unknown, Not Known if RET Rearrangement Analysis Was Performed, Investigative Report, malignant neck melanoma, MAPK, Not Known if TP53 Mutation Analysis Was Performed, modulation by symbiont of host system process, Alpha-thalassemia/mental retardation syndrome, Genetic Materials, NOS, Unknown if Radiation Was Administered as an Additional Treatment for a New Tumor Event, ATRX syndrome, serine protein kinase activity, DRaf1, PRPF10, Genetic Material, mapk, Unknown Family History Cardiovascular Disease or Cardiovascular Disease Risk Factors, Transphosphorylases, malignant lip melanoma, RAFB1, malignant ear melanoma, Mutated, protein glutamyl kinase activity, Unknown if Caffeine Consumption is Routine, Mucous Membrane, MRXHF1, Unknown History of Alcohol Use, common, SAP155, Unknown GENC, RAD54L, AX1, Adjuvant Post-operative Pharmaceutical Therapy Administration Unknown, DpERK, Identified, 2810441F20Rik, ErkA, MALIG MELANOMA SKIN NOS, spine, epsilon PKC, Neither, Gene Mutation Positive, Cistron, History of Medical Treatment Unknown, Protein Kinase, Unknown if New Disease is Multifocal, pERK, Additional Surgery for New Loco-Regional Tumor Event Unknown, F14N23_9, ribosomal S6 protein kinase activity, GroupII, NS6, Benign Neoplasm, NS5, NS7, Gene, Coding, Not Known if MGMT Promoter Methylation Testing Was Performed, neurofibromatosis, zone of skin melanoma (disease), protrusion, Proto-oncogene c-RAF, Unknown Transformation, Ultraviolet Black Light, serine(threonine) protein kinase activity, Stage Unspecified, Phosphotransferase, Raf1, melanoma of skin, telomeres, Genetic, Malignancy, Medical Coding, xp42, causes, Unknown if Patient was Previously Evaluated for Current Chief Complaint, p42 mitogen-activated protein kinase activity, ATP:protein phosphotransferase (MAPKK-activated) activity, Unrelated Attribution, Trp53, Ink4a|Arf, Device Status Unknown, CMM9, Raf-1, Gene Mutant Positive, CMM2, JMS, ATMPK1, DmERK-A, Average Daily Use Smokeless Tobacco after Use for Six Weeks Unknown, Unknown History of Rheumatic Fever, FORMER, Mucosa, Tumor Reoccurrence Unknown After Initial Treatment, World, 2810001M05Rik, prkm2, prkm1, CT39192, l(1)2Fe, malignant melanoma of skin stage unspecified, Resolved, Cistrons, Phosphotransferases, Unknown when Chief Complaint Present, p38delta, Melanomas, twitchin kinase activity, Raf/phl, Sequence, EST2, CMNS, Ink4a/Arf, Telomeres, Unknown Release Mechanism of Action, B-raf, threonine-specific protein kinase activity, Not Known if KIT Mutation Analysis Was Performed, Physician Diagnosed Diabetes Unknown, frequent, B230398H18Rik, EY2-2, Unknown History of Neonatal Complication, Interferon Gamma Treatment Administration 90 Days Prior to Specimen Resection Unknown, l(1)ph, 11-29, Gene Variation Positive, acral melanoma, malignant upper limb melanoma, EPHT3, cardinality, AW494271, malignant melanoma, assay, Raf, Additional Surgery for New Metastatic Tumor Event Unknown, Greater, CG2845"],"additional_accession":[]},"is_claimable":false,"name":"20201006_EGA_MELA_CRKL - samples","description":"Illumina RNASeq sequencing of tumour samples from 53 cases of cutaneous melanoma and 61 cases of acral melanoma","dates":{"updated":"2022-08-30 18:10:03"},"accession":"EGAD00001006439","cross_references":{"TAXONOMY":["9606"],"pubmed":["28467829"],"EGA":["EGAC00001000010","EGAS00001001552"]}}